Other News To Note
Tuesday, December 20, 2011
The ALS Therapy Development Institute entered a research agreement with Biogen Idec Inc., of Cambridge, Mass., and UCB Pharma SA, of Brussels, Belgium, to investigate the use of an anti-CD40L antibody as a potential therapy for amyotrophic lateral sclerosis (ALS).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.